Page contents Key factsDecisionRelated medicine informationKey facts Invented name Nexpovio Active Substance Selinexor Therapeutic area Oncology Decision number P/0364/2021 PIP number EMEA-002387-PIP02-21 Pharmaceutical form(s) Tablet Condition(s) / indication(s) Treatment of endometrial carcinoma Route(s) of administration Oral use Contact for public enquiries Karyopharm Europe GmbHE-mail: cnippgen@karyopharm.comTel: +4915118568262 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 08/09/2021DecisionP/0364/2021 : EMA decision of 8 September 2021 on the granting of a product specific waiver for selinexor (Nexpovio), (EMEA-002387-PIP02-21)AdoptedReference Number: EMA/440048/2021 English (EN) (213.04 KB - PDF)First published: 10/01/2023ViewRelated medicine informationNexpovioShare this page